Research progress on symptom cluster assessment tools for patients with inflammatory bowel disease_West China Medical Journal

Authors：

WEI Rongsai ¹ , LI Xumiao ¹ , LIANG Zhuolin ¹ , ZHANG Nan ² , LIU Jingying ¹ ,  MA Hongwen ³

1. School of Nursing, Tianjin University of Traditional Chinese Medicine, Tianjin 300000, P. R. China;
2. Department of Colorectal, Tianjin Union Medical Center, the First Affiliated Hospital of Nankai University, Tianjin 300000, P. R. China;
3. Department of Nursing, Tianjin Union Medical Center, the First Affiliated Hospital of Nankai University, Tianjin 300000, P. R. China;

Corresponding?author：

MA Hongwen, Email: geilivable_mhw@126.com

Keywords：

Inflammatory bowel disease; symptom cluster; assessment tools; review

DOI：

10.7507/1002-0179.202506239

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Patients with inflammatory bowel disease (IBD) often face the complex challenge of multiple coexisting symptoms, and systematic assessment and management of symptom clusters are key to improving prognosis. This article provides a systematic review and analysis of domestic and international literature on symptom clusters in patients with IBD, briefly introduces the clinical characteristics of these symptom clusters, and summarizes the types, applicability, reliability, validity, and current application status of related assessment tools. At present, assessment tools for symptom clusters in patients with IBD still require optimization in terms of standardization and individualization. In the future, more precise symptom cluster management systems should be developed to provide a basis for research and clinical management of symptom clusters in these patients, thereby enhancing the precision of symptom management.

Citation： WEI Rongsai, LI Xumiao, LIANG Zhuolin, ZHANG Nan, LIU Jingying, MA Hongwen. Research progress on symptom cluster assessment tools for patients with inflammatory bowel disease. West China Medical Journal, 2026, 41(4): 687-692. doi: 10.7507/1002-0179.202506239 Copy

1.	魏娟, 汪芳裕. 美國炎癥性腸病新近共識和指南述要. 中國中西醫結合消化雜志, 2024, 32(8): 683-688.
2.	李學鋒, 彭霞, 周明歡. 我國炎癥性腸病流行病學研究進展. 現代消化及介入診療, 2020, 25(9): 1265-1267.
3.	Johansen I, Sm?stuen MC, L?kkeberg ST, et al. Symptoms and symptom clusters in patients newly diagnosed with inflammatory bowel disease: results from the IBSEN III study. BMC Gastroenterol, 2023, 23(1): 255.
4.	Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum, 2001, 28(3): 465-470.
5.	Kim HJ, McGuire DB, Tulman L, et al. Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs, 2005, 28(4): 270-282.
6.	Fairbrass KM, Guthrie EA, Black CJ, et al. Characteristics and effect of anxiety and depression trajectories in inflammatory bowel disease. Am J Gastroenterol, 2023, 118(2): 304-316.
7.	Byale A, Lennon RJ, Byale S, et al. High-dimensional clustering of 4000 irritable bowel syndrome patients reveals seven distinct disease subsets. Clin Gastroenterol Hepatol, 2024, 22(1): 173-184. e12.
8.	Zhang J, Wang S, Wang Y, et al. Symptom clusters and network analysis in patients with gynecologic cancer undergoing chemotherapy: a cross-sectional study. Asia Pac J Oncol Nurs, 2024, 11(12): 100612.
9.	Zhu C, Wang N, Xu F, et al. Exploration of symptom cluster patterns and their trajectory in esophageal cancer surgery patients. Eur J Oncol Nurs, 2025, 74: 102801.
10.	Yang P, Mei HJ, Zhao HY, et al. Exploring symptom cluster patterns in adult cancer patients undergoing chemotherapy:a systematic review. J Korean Acad Nurs, 2024, 54(4): 478-494.
11.	Zhijia S, Meijuan X, Yanting Z, et al. Illness perceptions as a predictor of symptom cluster trajectories in patients with inflammatory bowel disease: a latent growth mixture model. Gastroenterol Nurs, 2024, 47(2): 111-121.
12.	Touma Z, Hoskin B, Atkinson C, et al. Systemic lupus erythematosus symptom clusters and their association with patient-reported outcomes and treatment: analysis of real-world data. Arthritis Care Res (Hoboken), 2022, 74(7): 1079-1088.
13.	Barnes A, Toson B, Bryant RV, et al. Latent profiles of fatigue in inflammatory bowel disease. BMC Gastroenterol, 2024, 24(1): 148.
14.	Riggott C, Fairbrass KM, Black CJ, et al. Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: prospective longitudinal follow-up study. Aliment Pharmacol Ther, 2023, 58(11/12): 1163-1174.
15.	Riggott C, Ford AC, Gracie DJ. Review article: the role of the gut-brain axis in inflammatory bowel disease and its therapeutic implications. Aliment Pharmacol Ther, 2024, 60(9): 1200-1214.
16.	Dunleavy KA, Raffals LE, Camilleri M. Intestinal barrier dysfunction in inflammatory bowel disease: underpinning pathogenesis and therapeutics. Dig Dis Sci, 2023, 68(12):4306-4320.
17.	Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology, 1989, 96(3): 804-810.
18.	周薇, 尤黎明, 李瑜元, 等. 中文版炎癥性腸病問卷的信度和效度研究. 國際護理學雜志, 2006(8): 620-622.
19.	潘靜聰, 李紅, 洪燕玲. 炎癥性腸病患者益處發現與自我管理行為及生活質量的關系研究. 護理與康復, 2025, 24(2): 13-17,423.
20.	Irvine EJ, Zhou Q, Thompson AK. The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT investigators. Canadian Crohn’s relapse prevention trial. AmJ Gastroenterol, 1996, 91(8): 1571-1578.
21.	Best WR, Becktel JM, Singleton JW, et al. Development ofa Crohn’s disease activity index. National cooperative Crohn’s disease study. Gastroenterology, 1976, 70(3): 439-444.
22.	楊莉麗, 江丹玲, 陳文科, 等. 克羅恩病患者血清總 25 羥維生素 D 及細胞因子水平表達與疾病活動指數的相關性研究. 現代檢驗醫學雜志, 2022, 37(1): 195-198.
23.	殷滋, 王修石, 彭紹賢. 平均血小板體積/淋巴細胞比值與克羅恩病患者內鏡評分、疾病活動度的關系. 轉化醫學雜志, 2024, 13(2): 203-207.
24.	Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis:a randomised trial. BMJ, 1989, 298(6666): 82-86.
25.	朱宇. 三香排氣飲治療脾虛氣滯兼濕熱型潰瘍性結腸炎的療效觀察. 鄭州: 河南中醫藥大學, 2023.
26.	魏威, 李龍, 袁秀梅, 等. 健脾愈瘍湯結合美沙拉嗪對潰瘍性結腸炎患者 UCAI、CRP 及 ESR 的影響. 中醫臨床研究, 2018, 10(24): 77-78.
27.	Moein A, Langenhorst J, Plan EL, et al. A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score. Clin Transl Sci, 2023, 16(11): 2310-2322.
28.	Sandborn WJ, Sands BE, Uddin S, et al. Clinical trial design in ulcerative colitis: interpreting evolving endpoints based on post hoc analyses of the vedolizumab phase 3 trials GEMINI 1 and VISIBLE 1. Crohns Colitis 360, 2023, 6(1): otad76.
29.	Sandborn WJ, Sands BE, Vermeire S, et al. Modified mayo score versus mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program. Ther Adv Gastroenterol, 2022, 15: 17562848221136331.
30.	Sexton KA, Walker JR, Targownik LE, et al. The inflammatory bowel disease symptom inventory: a patient-report scale for research and clinical application. Inflamm Bowel Dis, 2019, 25(8): 1277-1290.
31.	陳夢雪, 王宏剛, 謝睿. 炎癥性腸病癥狀量表在炎癥性腸病中的應用. 中國臨床研究, 2023, 36(1): 50-54.
32.	劉展鵬, 楊曉鐘, 陳夢雪, 等. 炎癥性腸病癥狀量表評估炎癥性腸病疾病活動度的臨床價值研究. 中國全科醫學, 2022, 25(14): 1713-1718.
33.	羅娜, 阮艷琴, 雷平光, 等. 炎癥性腸病患者報告結局測定量表的測量學特性分析. 中國全科醫學, 2023, 26(36): 4602-4607.
34.	Bodger K, Ormerod C, Shackcloth D, et al. Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-control questionnaire. Gut, 2014, 63(7): 1092-1102.
35.	顧芳臣, 林征, 尚星辰, 等. 炎癥性腸病患者癥狀群評估量表的編制及信效度檢驗. 中華護理雜志, 2020, 55(12): 1819-1824.
36.	關清, 崔妙玲, 莫焱, 等. 潰瘍性結腸炎患者癥狀群及其影響因素分析. 護士進修雜志, 2021, 36(21): 1926-1931.
37.	張曙鈴. 隔藥灸為主對脾腎陽虛型潰瘍性結腸炎患者外周血 th17 細胞水平影響的臨床觀察. 福州: 福建中醫藥大學, 2019.
38.	徐巖, 秦亞玲, 李欣. 炎癥性腸病病人癥狀群評估量表的應用價值分析. 循證護理, 2022, 8(11): 1538-1541.
39.	董萍萍, 呂紅莉, 高敏, 等. 炎癥性腸病核心癥狀量表構建//第五屆全國醫藥研究論壇論文集(一). 西安: 榆林市醫學會, 2024.

1. 魏娟, 汪芳裕. 美國炎癥性腸病新近共識和指南述要. 中國中西醫結合消化雜志, 2024, 32(8): 683-688.
2. 李學鋒, 彭霞, 周明歡. 我國炎癥性腸病流行病學研究進展. 現代消化及介入診療, 2020, 25(9): 1265-1267.
3. Johansen I, Sm?stuen MC, L?kkeberg ST, et al. Symptoms and symptom clusters in patients newly diagnosed with inflammatory bowel disease: results from the IBSEN III study. BMC Gastroenterol, 2023, 23(1): 255.
4. Dodd MJ, Miaskowski C, Paul SM. Symptom clusters and their effect on the functional status of patients with cancer. Oncol Nurs Forum, 2001, 28(3): 465-470.
5. Kim HJ, McGuire DB, Tulman L, et al. Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs, 2005, 28(4): 270-282.
6. Fairbrass KM, Guthrie EA, Black CJ, et al. Characteristics and effect of anxiety and depression trajectories in inflammatory bowel disease. Am J Gastroenterol, 2023, 118(2): 304-316.
7. Byale A, Lennon RJ, Byale S, et al. High-dimensional clustering of 4000 irritable bowel syndrome patients reveals seven distinct disease subsets. Clin Gastroenterol Hepatol, 2024, 22(1): 173-184. e12.
8. Zhang J, Wang S, Wang Y, et al. Symptom clusters and network analysis in patients with gynecologic cancer undergoing chemotherapy: a cross-sectional study. Asia Pac J Oncol Nurs, 2024, 11(12): 100612.
9. Zhu C, Wang N, Xu F, et al. Exploration of symptom cluster patterns and their trajectory in esophageal cancer surgery patients. Eur J Oncol Nurs, 2025, 74: 102801.
10. Yang P, Mei HJ, Zhao HY, et al. Exploring symptom cluster patterns in adult cancer patients undergoing chemotherapy:a systematic review. J Korean Acad Nurs, 2024, 54(4): 478-494.
11. Zhijia S, Meijuan X, Yanting Z, et al. Illness perceptions as a predictor of symptom cluster trajectories in patients with inflammatory bowel disease: a latent growth mixture model. Gastroenterol Nurs, 2024, 47(2): 111-121.
12. Touma Z, Hoskin B, Atkinson C, et al. Systemic lupus erythematosus symptom clusters and their association with patient-reported outcomes and treatment: analysis of real-world data. Arthritis Care Res (Hoboken), 2022, 74(7): 1079-1088.
13. Barnes A, Toson B, Bryant RV, et al. Latent profiles of fatigue in inflammatory bowel disease. BMC Gastroenterol, 2024, 24(1): 148.
14. Riggott C, Fairbrass KM, Black CJ, et al. Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: prospective longitudinal follow-up study. Aliment Pharmacol Ther, 2023, 58(11/12): 1163-1174.
15. Riggott C, Ford AC, Gracie DJ. Review article: the role of the gut-brain axis in inflammatory bowel disease and its therapeutic implications. Aliment Pharmacol Ther, 2024, 60(9): 1200-1214.
16. Dunleavy KA, Raffals LE, Camilleri M. Intestinal barrier dysfunction in inflammatory bowel disease: underpinning pathogenesis and therapeutics. Dig Dis Sci, 2023, 68(12):4306-4320.
17. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology, 1989, 96(3): 804-810.
18. 周薇, 尤黎明, 李瑜元, 等. 中文版炎癥性腸病問卷的信度和效度研究. 國際護理學雜志, 2006(8): 620-622.
19. 潘靜聰, 李紅, 洪燕玲. 炎癥性腸病患者益處發現與自我管理行為及生活質量的關系研究. 護理與康復, 2025, 24(2): 13-17,423.
20. Irvine EJ, Zhou Q, Thompson AK. The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT investigators. Canadian Crohn’s relapse prevention trial. AmJ Gastroenterol, 1996, 91(8): 1571-1578.
21. Best WR, Becktel JM, Singleton JW, et al. Development ofa Crohn’s disease activity index. National cooperative Crohn’s disease study. Gastroenterology, 1976, 70(3): 439-444.
22. 楊莉麗, 江丹玲, 陳文科, 等. 克羅恩病患者血清總 25 羥維生素 D 及細胞因子水平表達與疾病活動指數的相關性研究. 現代檢驗醫學雜志, 2022, 37(1): 195-198.
23. 殷滋, 王修石, 彭紹賢. 平均血小板體積/淋巴細胞比值與克羅恩病患者內鏡評分、疾病活動度的關系. 轉化醫學雜志, 2024, 13(2): 203-207.
24. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis:a randomised trial. BMJ, 1989, 298(6666): 82-86.
25. 朱宇. 三香排氣飲治療脾虛氣滯兼濕熱型潰瘍性結腸炎的療效觀察. 鄭州: 河南中醫藥大學, 2023.
26. 魏威, 李龍, 袁秀梅, 等. 健脾愈瘍湯結合美沙拉嗪對潰瘍性結腸炎患者 UCAI、CRP 及 ESR 的影響. 中醫臨床研究, 2018, 10(24): 77-78.
27. Moein A, Langenhorst J, Plan EL, et al. A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score. Clin Transl Sci, 2023, 16(11): 2310-2322.
28. Sandborn WJ, Sands BE, Uddin S, et al. Clinical trial design in ulcerative colitis: interpreting evolving endpoints based on post hoc analyses of the vedolizumab phase 3 trials GEMINI 1 and VISIBLE 1. Crohns Colitis 360, 2023, 6(1): otad76.
29. Sandborn WJ, Sands BE, Vermeire S, et al. Modified mayo score versus mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program. Ther Adv Gastroenterol, 2022, 15: 17562848221136331.
30. Sexton KA, Walker JR, Targownik LE, et al. The inflammatory bowel disease symptom inventory: a patient-report scale for research and clinical application. Inflamm Bowel Dis, 2019, 25(8): 1277-1290.
31. 陳夢雪, 王宏剛, 謝睿. 炎癥性腸病癥狀量表在炎癥性腸病中的應用. 中國臨床研究, 2023, 36(1): 50-54.
32. 劉展鵬, 楊曉鐘, 陳夢雪, 等. 炎癥性腸病癥狀量表評估炎癥性腸病疾病活動度的臨床價值研究. 中國全科醫學, 2022, 25(14): 1713-1718.
33. 羅娜, 阮艷琴, 雷平光, 等. 炎癥性腸病患者報告結局測定量表的測量學特性分析. 中國全科醫學, 2023, 26(36): 4602-4607.
34. Bodger K, Ormerod C, Shackcloth D, et al. Development and validation of a rapid, generic measure of disease control from the patient’s perspective: the IBD-control questionnaire. Gut, 2014, 63(7): 1092-1102.
35. 顧芳臣, 林征, 尚星辰, 等. 炎癥性腸病患者癥狀群評估量表的編制及信效度檢驗. 中華護理雜志, 2020, 55(12): 1819-1824.
36. 關清, 崔妙玲, 莫焱, 等. 潰瘍性結腸炎患者癥狀群及其影響因素分析. 護士進修雜志, 2021, 36(21): 1926-1931.
37. 張曙鈴. 隔藥灸為主對脾腎陽虛型潰瘍性結腸炎患者外周血 th17 細胞水平影響的臨床觀察. 福州: 福建中醫藥大學, 2019.
38. 徐巖, 秦亞玲, 李欣. 炎癥性腸病病人癥狀群評估量表的應用價值分析. 循證護理, 2022, 8(11): 1538-1541.
39. 董萍萍, 呂紅莉, 高敏, 等. 炎癥性腸病核心癥狀量表構建//第五屆全國醫藥研究論壇論文集(一). 西安: 榆林市醫學會, 2024.

West China Medical Journal

Research progress on symptom cluster assessment tools for patients with inflammatory bowel disease

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content